VNS stands as an efficacious treatment across diverse neurological and psychiatric conditions. To comprehensively grasp its impact on cognitive function, delving into its effects on both cognitively impaired patients and healthy individuals is imperative, ensuring a holistic understanding.

Given the sensitivity of VNS outcomes to stimulation parameters, it is crucial to optimize responses for various clinical indications. To determine optimal parameters, four stimulation frequencies (2, 10, 25, and 100 Hz) were tested in healthy individuals using functional MRI (fMRI) on the NTS (Sclocco et al., 2020). The study found that all frequencies were effective, with 100 Hz showing the strongest brainstem responses and increased activation in monoamine neurotransmitter and pain-related nuclei.

According to conflict monitoring theory, processing situational signals like perceptual response conflict is crucial for balancing shielding and relaxation, which enhances cognitive control. To validate this theory, Fischer et al. (2018) administered left ear transcutaneous VNS to students, with average stimulation intensities of 1.3 mA in the active group and 1.49 mA in the sham group. They assessed changes in N2 and P3 event-related potentials (ERPs) and conflict task performance. The results showed reduced conflict interference and N2 and P3 amplitude post-conflict, with VNS treatment notably improving adaptation to conflict and increasing N2 amplitude (Fischer et al., 2018).

Perseverative cognitions can induce stress even without an actual stressor present. To examine the impact of non-invasive VNS on cognitive and autonomic responses to perseverative cognition after a psychosocial stress task, researchers conducted a trial using taVNS treatment on healthy individuals. The findings showed that taVNS notably decreased cognitive rigidity, as evidenced by decreased subjective perseverative thinking post-psychosocial stress (De Smet et al., 2023).

As mentioned above, research has demonstrated the beneficial impact of taVNS on cognitive function in healthy individuals, particularly in enhancing attention, memory, executive function, and cognitive control in singular tasks (Borges et al., 2020; Colzato and Beste, 2020). However, in multitasking scenarios, the concurrent processing of various stimuli creates challenges in stimulus-response (S-R) translation. Consequently, exploring the influence of taVNS on multitasking abilities becomes imperative (Logan and Delheimer, 2001). Sommer et al. (2023) recruited healthy participants aged 18–30 to engage in a dual-task paradigm under taVNS stimulation. They assessed behavioral performance, primarily focusing on reaction time, across three cognitive test blocks, and the results indicated a notable increase in inter-task interference during the initial test block, while not in the subsequent blocks during taVNS treatment (Sommer et al., 2023). While another study investigated the impact of transcutaneous VNS on the cognitive flexibility of healthy individuals, it found that tVNS may affect the LC-NE system, as indicated by the secretion of NE, dopamine, and serotonin. However, the researchers found no significant difference in task-switching ability, which referred to the ability to switch quickly between two or more cognitive tasks (Tona et al., 2020).

Previous studies have preliminarily explored the cognitive effects of various pathologies in animal models after extended VNS procedures (Wang et al., 2016; Yu et al., 2018). However, chronic VNS suffers from the shortcomings of a long treatment cycle, and the understanding of the mechanisms and effects associated with VNS can be further expanded by conducting studies related to acute VNS in animal models. Research revealed that acute VNS treatment enhanced short-term memory and cognitive flexibility in naïve rats, with no significant correlation between cognitive effects and VNS-induced non-specific alterations in motor functions or anxiety levels (Driskill et al., 2022). Furthermore, following a single 30-min session of invasive VNS, stimulated rats showed enhanced performance in behavioral tests, along with increased long-term potentiation (LTP), spontaneous spike amplitude, frequency, and elevated brain-derived neurotrophic factor (BDNF) levels in the CA1of hippocampus (Olsen et al., 2022). The above studies demonstrated that chronic VNS could enhance cognition and task processing, while short-term VNS may also improve cognitive flexibility, supporting the promotion of this promising treatment modality.

Cognitive studies have implicated epigenetic mechanisms such as RNA-DNA-protein interactions, DNA methylation, and chromatin remodeling to effective learning and memory (Breen et al., 2024; Wilson et al., 2023). Thus, Sanders et al. (2019) examined the epigenetic changes in hippocampal and cortical regions following VNS treatment (100 μs biphasic pulses, 30 Hz, 0.8 mA) in healthy rats for 4 days to elucidate the mechanisms underlying VNS effects on cognitive functions. They observed a significant correlation between performance in the novelty preference test (NPTP) and epigenetic changes, specifically reduced HDAC11 levels in the hippocampus and elevated IEG ARC levels in the cerebral cortex. These changes, linked to plasticity genes such as HDAC3 and transcriptional regulators, implicate histone acetylation and alterations in hippocampal and cortical HDAC in VNS-mediated modulation of stress response, neuronal plasticity, and memory consolidation.

To improve working memory while mitigating taVNS-related deficiencies, recent researchers developed a novel and practical vibrotactile taVNS system. The results suggest that 6 Hz vibrotactile auricular VNS holds promise as an intervention for enhancing working memory performance as it may boost general arousal and counteract decreases in arousal during continuous working memory tasks in healthy individuals (Tan et al., 2024).

AD is a multifaceted neurodegenerative disorder impacting over 30 million people globally. It is influenced by factors such as age, gender, genetics, lifestyle, gut microbiota, and personal brain disease history (Hu et al., 2021; Mazure and Swendsen, 2016; Rajendran and Krishnan, 2024). Traditional single-mechanism interventions have shown limited efficacy, prompting the exploration of novel strategies, including nano-drug delivery systems, immune response modulation for amyloid clearance, and neuron replacement with stem cells (Almuhayawi et al., 2020; Cone et al., 2021; Song et al., 2022). While these emerging approaches show promise, they require further clinical validation. AD is characterized by multiple pathological mechanisms, including Tau hyper-phosphorylation (Chiasseu et al., 2017; Goedert et al., 1988; Hausrat et al., 2022), mitochondrial dysfunction (Wang et al., 2020; Zhang et al., 2023), synaptic loss (Forner et al., 2017; Pereira et al., 2021; Zhong et al., 2023), and cholinergic system impairment (Giacobini et al., 2022; Hampel et al., 2018; Schumacher et al., 2022). Research indicates that somatosensory stimulation may enhance hippocampal activity and acetylcholine release61, whereas VNS could improve motor refinement via cholinergic signaling (Bowles et al., 2022).

Previous research on VNS in AD patients has produced conflicting results. One open-label pilot study indicated that VNS can mitigate cognitive decline after 3 months of treatment, with 7 out of 10 patients showing improvement assessed by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog, median improvement of 3.0 points) and 9 out of 10 patients showing improvement assessed by Mini-Mental State Examination (MMSE, median improvement 1.5 points). After 6 months of treatment, a similar effect of improved cognitive function was demonstrated (Sjögren et al., 2002). Merrill et al.’s (2006) study showed no significant cognitive decline in 12 out of 17 patients after 1 year of VNS treatment measured by MMSE and ADAS-cog. However, other studies have reported limited cognitive improvement.

Mild cognitive impairment (MCI) frequently precedes dementia, manifesting as relatively preserved daily functioning alongside documented cognitive decline. The transition from MCI to dementia is conservatively estimated at 5%–10% annually, with comparable rates observed for regression from MCI to normal cognition. Thus, MCI is an unstable cognitive state, and effective interventions for this group of patients have the potential to reduce the transition to dementia and mitigate the ensuing social sequelae. Luijpen et al. (2004) conducted two independent studies focusing on the effects of transcutaneous electrical nerve stimulation (TENS) on older patients with MCI, one study delved into self-efficacy and mood, and the other centered on memory (location: between the 1st and 5th thoracic level on each side of the spinal column) (Luijpen et al., 2005). TENS treatment showed moderate improvement in cognitive function (measured by the MMSE scale), self-efficacy (measured by the Groninger Activity Restriction Scale and Philadelphia Geriatric Center Morale Scale), and mood (measured by the Geriatric Depression Scale). It is notable that while previous research has indicated that TENS (location: on the back between Th1 and Th5) has a positive impact on memory function in AD patients, particularly those in the early stages (Scherder and Bouma, 1999), Luijpen et al.’ (2005) study revealed that for individuals with MCI, TENS did not enhance their memory capacity. The reason for this paradoxical result may be the distinct responses of the cholinergic system to TENS at different stages of the disease course of AD-related cognitive impairment. Primarily, ChAT activity levels in the CSF, prefrontal cortex, and hippocampus of MCI patients surpass those of both normal elderly individuals and AD patients (DeKosky et al., 2002; Karami et al., 2021). TENS, through its stimulation of cholinergic basal forebrain neurons, might intensify activation in the prefrontal cortex and hippocampus. Essentially, this could lead to an overactivation of the cholinergic system, potentially yielding ineffective or even adverse outcomes.

Given that individuals with MCI possess a dual potential for transitioning either toward dementia or retaining normal cognitive function, interventions at this stage hold significant clinical importance. Consequently, recent research has predominantly concentrated on patients with MCI, particularly exploring VNS. Wang et al. (2022) demonstrated noteworthy alterations in cognitive function rating scales, such as Montreal cognitive assessment-basic (MoCA-B), auditory verbal learning test-HuaShan version (AVLT-H), and shape trail test (STTB), following 24 weeks of taVNS treatment for MCI patients. Furthermore, employing fMRI techniques, researchers observed alterations in functional connectivity among brain regions crucial for semantic and salience functions, notably involving temporal and parietal regions, in MCI patients undergoing tVNS. Additionally, connectivity originating from the hippocampus to various cortical and subcortical regions of interest (ROI) clusters exhibited changes with tVNS compared to ear lobe stimulation. In summary, tVNS induced modifications in brain region connectivity networks associated with the progression of AD, thereby providing insights for potential treatment strategies or mitigation of AD-related cognitive impairments (Murphy et al., 2023).

Although the results of available studies have been inconclusive, a synthesis of relevant studies on VNS and AD indicates that VNS may be an effective method of preventing further deterioration of cognitive function or even enhancing it. However, the impact of different AD disease stages on VNS efficacy should also be fully considered when applying it to clinical practice.

In addition to VNS, TENS has also been reported as a therapeutic option for addressing cognitive dysfunction in AD patients. To investigate the impact of TENS on cognitive function, Scherder et al. (1992, 1998, 2000) conducted a series of studies. Initially, they examined the effects of TENS treatment on patients with Alzheimer’s-type dementia, revealing a significant improvement in verbal long-term memory. However, no significant effects were observed on visual long-term memory, as well as verbal and non-verbal short-term memory (Scherder et al., 1992). Subsequently, considering potential environmental influences on treatment outcomes, they explored the efficacy of TENS in AD treatment when administered without therapists. This investigation also demonstrated cognitive enhancement with this treatment protocol (Scherder et al., 1998). Finally, they investigated the cognitive and behavioral effects of TENS in non-demented older adults, revealing improvements in visual short-term and verbal long-term (recognition) memory, as well as semantic verbal fluency. Additionally, these older adults were less likely to exhibit depressive-like moods (Scherder et al., 2000). However, another randomized controlled trial showed that in aged AD patients, TENS treatment (100 μs biphasic pulses, 160 Hz, location on the back at the first thoracic vertebra) did not result in significant changes in cognitive functioning as measured by Digit Span, Face Recognition on the Rivermead Behavioral Memory Test, and the Eight Word Test on the Amsterdam Dementia Screening Test (van Dijk et al., 2005).

In particular, it is observed that the majority of the studies included in this review, which investigate the effects of PNS in this demographic, primarily concentrate on individuals with MCI or AD. However, these studies do not extensively examine the underlying mechanisms through which PNS might influence cognitive function in these conditions. Additionally, the studies are generally characterized by short durations, with the maximum follow-up period extending to only one year. These limitations impede a comprehensive understanding of the therapeutic potential of PNS in AD and constrain its broader clinical application. Nonetheless, the extant evidence indicates that PNS may represent a promising approach to mitigating cognitive decline associated with AD and related disorders.

Epilepsy is a common chronic neurological disease of the CNS, which is featured by recurrent unprovoked seizures. According to the latest research on the global burden of neurological diseases, epilepsy ranks among the top ten conditions with the highest age-standardized DALYs in 2021 (GBD 2021 Nervous System Disorders Collaborators, 2024). Despite the approval and widespread adoption of innovative antiseizure medications (ASMs) over recent decades, up to one-third of individuals with epilepsy (PWE) continue to experience seizures despite treatment (Sultana et al., 2021). As epilepsy progresses, some patients may experience cognitive impairment. Given its efficacy in treating CNS disorders, VNS has been successfully used in patients with refractory epilepsy, including pediatric patients (Drees et al., 2024; Haddad et al., 2023; Seth et al., 2024). As VNS influences the functioning of specific brain regions, it’s crucial also to consider its potential effects on cognitive functioning when administering VNS therapy to patients with epilepsy.

In a clinical study investigating the impact of VNS on cognition and quality of life, it was found that after 12–14 weeks of treatment, VNS administered at higher stimulus intensities (as used clinically) did not yield significant alterations in cognitive functioning in either group. However, patients receiving higher stimulus intensities (as used clinically) reported experiencing fewer emotional and physical issues compared to those receiving lower stimulus intensities (minimal intensity) (Dodrill and Morris, 2001). Yet, a recent case report of two young female epilepsy patients showed that after 20 weeks of taVNS therapy, both achieved seizure freedom and improved quality-of-life scores (Shiraishi et al., 2024). Interestingly, the role of the VNS showed inconsistent effects on cognition when multiple cognitive function rating scales were included. Ghacibeh et al. (2006) compared the effects of actual and sham stimuli delivered by an implantable VNS device across various cognitive tasks, including assessments of cognitive flexibility, creativity, and memory. The results indicated that while VNS impaired cognitive flexibility and creativity, it did not negatively impact learning, and even enhanced attention.

Epilepsy is reported to be the third leading cause of DALYs among children and adolescents aged 5–19 years (GBD 2021 Nervous System Disorders Collaborators, 2024). A study of VNS in children with refractory epilepsy showed that after VNS treatment, seizure frequency resolved in 6/15 of the children, seizure completely resolved in one of the children, and QOL scores improved in 12 others; however, VNS did not appear to have a significant effect on cognitive function (Hallböök et al., 2005). Similarly, a randomized controlled study on children with intractable epilepsy found that after 20 weeks of iVNS treatment, while cognitive function remained unchanged, seizure frequency decreased, mood improved, and depression scores significantly lowered (Klinkenberg et al., 2013). Soleman et al. (2018) conducted a comparative analysis of children with epilepsy (aged < 12) undergoing VNS implantation and found no overall cognitive function changes; however, subgroup analysis showed significant cognitive improvement when VNS was implanted before age 5.

The researchers further investigated the impact of VNS on cognitive function in adults with medication-resistant epilepsy. Neuropsychological assessments were conducted both pre- and at least 6 months post-implantation of the stimulation device. Interestingly, the cognitive function evaluations revealed no significant differences in attention, learning and memory capacity, or short-term memory, and no adverse effects were observed after VNS (500 μs biphasic pulses, 30 Hz) (Hoppe et al., 2001). Furthermore, another study examining the effects of taVNS (250 μs biphasic pulses, 25 Hz) over 20 weeks in patients with drug-resistant epilepsy revealed no significant alterations in Montreal Cognitive Assessment (MoCA) scores, QOL scores, or mood scores [including measures such as Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), and Mini-International Neuropsychiatric Interview (MINI)]. Additionally, participants reported discomfort in the form of pain, sleep disturbances, and flu-like symptoms (Yang et al., 2023).

Two research groups investigated the effects of VNS on patients with drug-resistant epilepsy, comparing long-term [ Puteikis et al. (2023), lasting at least 24 months] and short-term [ Strong et al. (2018), 12 months] studies. After excluding participants with emotional and cognitive dysfunction, patients underwent treatment with different VNS frequencies. Theta frequency stimulation resulted in a 23% improvement in free recall, while beta and theta frequencies led to 5% and 15% reductions in accuracy and reaction time, respectively. In the short-term study, only one patient was ultimately enrolled. Meanwhile, a separate study on prolonged iVNS showed improvements in social cognition and short-term visual memory, as demonstrated by enhanced performance on the ROCF and Happé Strange Stories Test.

Patients with concurrent cognitive dysfunction and epilepsy often have additional neuropsychiatric conditions, such as cerebral palsy and autism spectrum disorder. Drug resistance in this group is notably high, around 45%. Although a retrospective study on patients with cognitive dysfunction and epilepsy undergoing iVNS therapy found that response rates were lower in those with both conditions, significant improvements in seizure reduction and alertness were noted (Pipan et al., 2020).

In addition to investigating VNS for epileptic patients, Wang et al. (2016) constructed a rodent epilepsy model by administering pilocarpine to explore the impact of another type of PNS-Transcutaneous nerve stimulation (TNS)-on epilepsy pathogenesis and cognitive function. The study’s findings revealed that immediate TNS treatment following the onset of epileptic seizures not only mitigated chronic spontaneous seizures but also ameliorated cognitive dysfunction in rats. These observed improvements may be attributed to TNS’s inhibitory effects on hippocampal apoptosis and the pro-inflammatory response (Wang et al., 2016).

The majority of studies included in the analysis of epilepsy treatments employed iVNS, which has been demonstrated to effectively reduce seizure frequency and, in certain instances, enhance cognitive function (Dodrill and Morris, 2001; Ghacibeh et al., 2006). Conversely, research examining non-invasive VNS in epilepsy patients has not consistently yielded significant cognitive improvements (Yang et al., 2023). The underlying reasons for this discrepancy between stimulation modalities remain unclear; however, they may be attributed to variations in stimulation parameters, the depth of nerve activation, or patient characteristics. This observation underscores the necessity for further investigation into the mechanisms driving these differences and advocates for the optimization and advancement of non-invasive VNS strategies, especially for epilepsy patients with concurrent cognitive impairments.

Postoperative cognitive dysfunction (POCD) is a neurological complication that can occur after surgery, resulting in cognitive decline due to neuroinflammation and oxidative stress triggered by the surgical procedure. Those affected often experience a debilitating condition. Individuals with POCD face an elevated risk of developing AD compared to those who age normally.

In a prospective double-blind randomized controlled trial conducted by Zhou et al. (2022), it was discovered that taVNS administered one hour before surgery and continued until the end of surgery effectively reduced the occurrence of delayed neurocognitive recovery (dNCR) in elderly patients one week after total joint arthroplasty. The incidence rate was notably lower in the taVNS group (10%) compared to the surgical group (27.1%). The study revealed significant reductions in neuroinflammation-related factors, such as IL-6, as well as markers of cholinesterase activity including AChE and BChE, in the serum of patients receiving taVNS. Furthermore, rodent experiments were carried out to investigate the mechanism through which taVNS mitigates postoperative cognitive impairment induced by the anesthetic drug sevoflurane in aged rats. The researchers concluded that taVNS attenuated sevoflurane-induced hippocampal neuronal apoptosis, necrosis, and microglia activation by activating the basal cholinergic system in the forebrain (Zhou et al., 2023). Another research team conducted a comparable study investigating the impact of preoperative VNS for 30 min on cognitive function in elderly rats using a POCD animal model induced by splenectomy (Xiong et al., 2019). Behavioral findings indicated a noteworthy extension in the avoidance latency of the Morris water maze (MWM) among rats treated with VNS, while no significant variance was observed in the results of the open field test (OFT). Subsequent investigation uncovered that surgery and anesthesia led to elevated levels of TNF-α and IL-6 in the serum, whereas VNS intervention mitigated the levels of these inflammatory factors. In addition, recent studies have revealed that auricular VNS exhibits the potential to ameliorate POCD-related neurological impairments in aged rats subjected to laparotomy. Notably, MWM test assessments indicated reduced swimming latency and distance, alongside significant improvements in neuroinflammation-related biomarkers, such as TNF-α, NF-κB, and IL-1β. Particularly noteworthy are the observed reductions in factors associated with the progression of AD, including attenuated tau phosphorylation at AT-8 and Ser396, and decreased levels of Aβ₄₀ and Aβ₄₂.

In summary, both clinical observations and mechanistic investigations underscore the promising role of VNS in mitigating POCD, offering optimistic prospects for perioperative cognitive preservation amid the prevalent occurrence and associated risks of POCD.

Traumatic Brain Injury (TBI) is a result of external force impacting the brain, standing as a primary cause of neurological disability and mortality globally. TBI encompasses various severity levels, including concussion and mild traumatic brain injury (mTBI), each capable of inducing cognitive deficits and impairment. Research indicates that approximately 65% of moderate to severe TBI patients experience enduring cognitive challenges, with up to 15% of mild TBI patients grappling with persistent cognitive impairment (Rabinowitz and Levin, 2014). However, the intricate nature of TBI poses challenges to effective treatment modalities, limiting the efficacy of current approaches in addressing and rehabilitating cognitive dysfunction (Galgano et al., 2017). Therefore, pursuing therapeutic interventions capable of ameliorating cognitive function in TBI patients holds paramount clinical significance.

Caloc’h et al. (2023) reported a case report involving a middle-aged male experiencing persistent cognitive dysfunction and intractable headaches following Traumatic Brain Injury (TBI). The utilization of bilateral Occipital Nerve Stimulation (ONS) in conjunction with multisite transcranial magnetic stimulation and cognitive training (cogT) yielded notable improvements in cognitive function, refractory pain, and depression in patients with TBI (Caloc’h et al., 2023). To elucidate the mechanism underlying the amelioration of cognitive function in TBI through neurostimulation, researchers conducted preliminary investigations using a rodent TBI model.

In a lateral fluid percussion injury (LFP) model of TBI, 14 days of VNS improved cognitive function in rats during the MWM test, but neurophysiological examination showed no significant changes in hippocampal lesions or neuron density (Smith et al., 2005). In a separate study, mice with TBI treated with TNS for 7 days showed improved cognitive function, with TNS enhancing hippocampal connectivity via corticotropin-releasing hormone (CRH) neurons in the paraventricular nucleus (PVN) and dopamine transporter (DAT) neurons in the substantia nigra compacta/ventral tegmental area (SNc/VTA) (Xu et al., 2023). These findings shed light on the specific mechanism by which TNS alleviates cognitive dysfunction in TBI.

To investigate the mechanism of taVNS in alleviating cognitive impairment from cerebrovascular disease, researchers used taVNS on an animal model of vascular cognitive impairment induced by transient bilateral common carotid artery occlusion (tBCCAO). Both short-term (2 days) and long-term (6 days) taVNS improved cognitive function and cerebrospinal fluid circulation, suggesting that taVNS enhances CSF flow and may effectively treat ischemic cognitive impairment (Choi et al., 2022). Given the close association between cholinergic neuroproteins and cognitive function, Wu et al. (2018) investigated whether tVNS could improve post-stroke cognitive dysfunction by modulating the non-neuronal cholinergic system in a rat middle cerebral artery occlusion (MCAO) model. They found that five days of tVNS alleviated cognitive impairment and altered key cholinergic factors in the hippocampus. Similarly, Liu et al. (2016) reported that VNS enhanced spatial and fear memory in a rat MCAO/R model, suggesting its potential to alleviate cognitive dysfunction, possibly through norepinephrine modulation.

Clinical studies on PNS’s impact on cognitive function post-stroke are limited, but one study showed significant cognitive improvements in patients with moderate-to-severe stroke-induced impairment after a 10-week, 20-session TENS regimen. Improvements were noted in verbal and visual memory, attention, and perception, while mood remained unaffected (Rorsman and Johansson, 2006). These findings suggest that PNS may benefit cognitive rehabilitation in ischemic stroke and cerebrovascular accident patients, though its mechanism remains unclear.

Major Depressive Disorder (MDD) is a widespread and severe mental illness linked with considerable morbidity and mortality. The World Health Organization predicts that by 2030, MDD will be a leading cause of global disease burden (Collins et al., 2011). Individuals with MDD often experience impairments in learning, memory, and executive functioning, and many do not achieve functional remission despite various treatments (Rosenblat et al., 2016). Thus, proactive intervention strategies are essential, particularly for those who do not respond to pharmacotherapy.

Following 10 weeks of VNS treatment for Treatment-Resistant Depression (TRD), a study by Sackeim et al. (2001) found no decline in neurocognitive function, with improvements in language, executive function, and psychomotor function compared to baseline. Similarly, a long-term study of VNS in TRD patients observed significant enhancements in learning and memory after one month, with cognitive improvements persisting for two years. Initially, there was no correlation between cognitive and depression scores, but a significant correlation developed after one year of treatment (Desbeaumes Jodoin et al., 2018).

The prevalence of Attention Deficit/Hyperactivity Disorder (ADHD) among children aged 4–17 years ranges from 5% to 11%, exerting not only a negative impact on the patient’s quality of life but also imposing a significant financial burden on their families (Kessler et al., 2006; Solanto et al., 2009). Despite pharmacotherapy being the most commonly employed treatment strategy for ADHD, it is fraught with challenges such as poor adherence and adverse effects. Previous studies have indicated that TNS may offer efficacy in alleviating ADHD symptoms. Loo et al. (2021) specifically investigated the response to TNS in children with ADHD exhibiting executive dysfunction. Their findings demonstrated that this subgroup of children exhibited a favorable response to TNS, characterized by altered brain activity in the right frontal lobe, normalization of executive functioning, and a reduction in ADHD symptoms. Moreover, a prior study suggested that TENS (location: on the patient’s back between Th1 and Th5) may modestly improve cognitive functioning in children with ADHD, particularly in terms of executive functioning (Jonsdottir et al., 2004).

To address the public health issue of fatigue, non-invasive neuromodulation, specifically cranial transcutaneous VNS (ctVNS), was tested by McIntire et al. (2021) on 40 participants who underwent 34 h of wakefulness. The ctVNS group showed improved arousal, multitasking, and reported lower fatigue levels compared to the sham group, indicating ctVNS may effectively reduce fatigue (McIntire et al., 2021).

Epidemiological studies reveal that over 75% of cancer patients experience acute cognitive decline during chemotherapy, with approximately 17%–34% developing long-term cognitive impairment (Hede, 2008). Findings from a randomized controlled trial conducted by Zhang et al. (2020) demonstrated that electroacupuncture trigeminal nerve stimulation combined with body acupuncture (EA/TNS+BA) significantly enhanced cognitive performance levels in breast cancer patients undergoing chemotherapy. Specifically, after 2 and 8 weeks of treatment, patients exhibited significantly improved performance on the Reverse Digit Span Test. Moreover, the incidence of adverse events such as diarrhea, loss of appetite, headache, anxiety, and irritability significantly decreased. However, no significant changes were observed in MoCA scores or the incidence of chemobrain.

Animal model studies investigating cognitive dysfunction have demonstrated that VNS mitigates cognitive decline in obese insulin-resistant rats. This effect is attributed to VNS’s ability to alleviate mitochondrial dysfunction, enhance insulin sensitivity in the brain, increase dendritic spine density, and reduce cell apoptosis (Chunchai et al., 2016).